Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 10, 2006, Pages 1525-1532

  Kazim, Syed Naqui ^a   Chauhan, Ranjit ^a   Das, Bhudev Chandra ^b   Sarin, Shiv Kumar ^a  

^a G B PANT HOSPITAL   (India)

^b ICPO   (India)

Author keywords

Core promoter mutations; Hepatitis B virus; Lamivudine resistance; Viral breakthrough; YMDD mutation

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CAUSE OF DEATH; CHRONIC HEPATITIS; CLINICAL ARTICLE; DNA SEQUENCE; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; SEROCONVERSION; VIROLOGIC BREAKTHROUGH; VIRUS GENOME; VIRUS MUTANT; VIRUS MUTATION;

EID: 33747618007     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04513.x     Document Type: Article

References (19)

1. Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 1997; 337: 1733-45.
2. Liaw Y-F, Leung NWY, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172-80.
3. Leung NWY, Lai CL, Chang TT et al. Three year lamivudine therapy in chronic HBV. J. Hepatol. 1999; 30 (Suppl. 1): 59.
4. Chang TT, Lai CL, Liaw YF et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV patients treated with lamivudine for four years (abstract). Antivir. Ther. 2000; 5 (Suppl. 1): 44.
5. Tassopoulos NC, Anagnostopoulos GD, Delladetsima JK, Barbati C, Angelopoulou P, Sipsa V. Extended lamivudine treatment in patients with HBeAg negative/HBV DNA positive chronic hepatitis B. Hepatology 2000; 32: 456A.
6. Hadziyannis S, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847-51.
7. Wakil SM, Kazim SN, khan LA et al. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus. J. Med. Virol. 2002; 68: 311-18.
8. Ono-Nita SK, Kato N, Shiratori Y, Yoshida H, Carrilho FJ, Omata M. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J. Clin. Invest. 1999; 103: 1635-40.
9. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-72.
10. de Man RA, Bartholomew AI, Niesters HGM, Zondervan PE, Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J. Hepatol. 1998; 29: 669-75.
11. Kazim SN, Wakil SM, Khan LA, Hasnain SE, Sarin SK. Viral breakthrough in chronic hepatitis B patients in the absence of known lamivudine resistant mutants. J. Gastroenterol. Hepatol. 2002; 17 (Suppl.): A25.
12. Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-16.
13. Lau DTY, Kokhar MF, Doo E et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828-34.
14. Akuta N, Suzuki F, Suzuki Y et al. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study. J. Med. Virol. 2005; 75: 491-8.
15. Thabut D, Thibault V, Bernard-Chabert B et al. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur. J. Gastroenterol. Hepatol. 2004; 16: 1367-73.
16. Chang ML, Chien RN, Yeh CT, Liaw YF. Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. J. Hepatol. 2005; 43: 72-77.
17. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628-33.
18. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 219-26.
19. Li J, Buckwold VE, Hon MW, Ou JH. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. J. Virol. 1999; 73: 1239-44.